Stonegate Capital Partners Updates Coverage on Viemed Healthcare, Inc. (VMD) 4Q 2025

Stonegate Capital Partners has recently updated its coverage on Viemed Healthcare, Inc. (NASDAQ: VMD), revealing significant developments following the company’s impressive fiscal performance in 2025. Viemed reported a year-over-year revenue growth of 21%, reaching $270.3 million, alongside a net income of $14.9 million and an adjusted EBITDA of $61.4 million, marking a record achievement for the company. This growth trajectory has been propelled by a combination of robust platform momentum and contributions from the recent acquisition of Lehan's, as well as the ongoing shift to in-home care that has led to increased adoption of sleep and resupply solutions.

However, the company faced short-term challenges stemming from an updated National Coverage Determination (NCD) which introduced stricter documentation requirements and coverage criteria, temporarily impacting ventilator patient growth. Notably, these changes did not affect reimbursement levels, and Viemed is beginning to see a normalization in ventilator activity as operational adjustments are being made.

Ending FY25 on a high note, the company reported an impressive 141% increase in free cash flow, underscoring its financial health. Key observations from the report include the transition of sleep and resupply services becoming the primary revenue drivers, thus lessening regulatory risk while enhancing revenue quality. The acquisition of Lehan's is expected to broaden the company’s commercial reach and diversify payor relationships, providing a strong foundation for sustainable growth.

Looking ahead, despite some pressure on margins due to the mix, Stonegate's guidance for FY26 suggests that Viemed's growth potential remains undervalued, signaling an optimistic outlook for investors considering the company's evolving operational landscape and market positioning.

Stonegate Capital Partners' recent update on Viemed Healthcare, Inc. (NASDAQ: VMD) highlights a robust financial performance for FY25, underscoring the company's strategic positioning within the growing in-home care sector. With a remarkable 21% year-over-year growth in net revenue to $270.3 million and a significant increase in net income to $14.9 million, Viemed demonstrates resilience and potential for further expansion, particularly in the sleep and resupply segments, which are driving a shift away from traditional ventilation services.

Investors should take a closer look at Viemed’s evolving business model, especially with the integration of Lehan's, which not only enhances commercial reach but also diversifies the company's payer mix. This diversification is essential for establishing a more sustainable revenue base and mitigating regulatory risks associated with reliance on fewer payors. Moreover, with the recent difficulty from updated National Coverage Determination (NCD) guidelines—while it may have temporarily affected ventilator growth—it's crucial to note that reimbursement levels have remained stable and operational efficiencies are beginning to normalize.

The marked 141% year-over-year increase in free cash flow indicates a solid foundation for future investments and shareholder returns. Furthermore, the company's guidance for FY26, along with valuation metrics, suggests that current market perceptions may underappreciate Viemed’s durable growth prospects.

Given these insights, investors might consider adding VMD to their portfolios, keeping an eye on the evolving regulatory landscape and the company's strategic initiatives in expanding its sleep and resupply offerings. As the in-home healthcare sector continues to gain momentum, Viemed stands poised for continued success, making it a compelling investment opportunity for those seeking growth in the healthcare market.